Three genes were selected for validation at the protein level based on their high normalized counts, previously described function in myeloma, and accompanying primary antibody performance (in WB): (1) DDIT4 (also known as REDD-1), promotes myeloma cell growth and survival [50] and is described as a GC-inducible muscle atrophy marker [51]; (2) ERN1 (also known as IRE1α), a sensor of unfolded proteins and critical for MM tumor growth [52]; (3) POU2AF1 (also known as BOB-1), a regulator of oncogenic networks in myeloma [53]. The gene discussed is ERN1; the disease is Miyoshi myopathy.